Search

Preserved biospecimens held in biobank inventories and clinical archives are important resources for biomarker research. Recent advances in technologies have led to an increase in use of clinical archives in particular, in order to study retrospective cohorts and to generate data relevant to tissue biomarkers. This raises the question of whether the current sizes of biobank inventories are appropriate to meet the demands of biomarker research. This commentary discusses this question by considering data concerning overall biobank and biospecimen numbers to estimate current biospecimen supply and use. The data suggests that biospecimen supply exceeds current demand. Therefore, it may be important for individual biobanks to reassess the targets for their inventories, consider culling unused portions of these inventories, and shift resources towards providing prospective custom biobanking services.

Human health biobanks are forms of research infrastructure that supply biospecimens and associated data to researchers, and therefore juxtapose the activities of clinical care and biomedical research. The discipline of biobanking has existed for over 20 years and is supported by several international professional societies and dedicated academic journals. However, despite both rising research demand for human biospecimens, and the growth of biobanking as an academic discipline, many individual biobanks continue to experience sustainability challenges. This commentary will summarize how the COVID-19 pandemic is creating new challenges and opportunities for both the health biobanking sector and the supporting discipline of biobanking. While the challenges for biobanks may be numerous and acute, there are opportunities for both individual biobanks and the discipline of biobanking to embrace change such that biobanks can continue to support and drive biomedical research. We will therefore describe numerous practical steps that individual biobanks and/or the discipline of biobanking can take to survive and possibly thrive in response to the COVID-19 pandemic.

Aims and Scope: This editorial announces the new Biomarker Insights Editor-in-Chief. The journal will continue to publish high-quality original reports and review articles in all areas of biomarker research, and will welcome submissions that focus on improving the quality of the biomarker research literature.

A major reason for biomarker failure is the selection of candidate biomarkers based on inaccurate or incorrect published results. Incorrect research results leading to the selection of unproductive biomarker candidates are largely considered to stem from unintentional research errors. The additional possibility that biomarker research may be actively misdirected by research fraud has been given comparatively little consideration. This review discusses what we believe to be a new threat to biomarker research, namely, the possible systematic production of fraudulent gene knockdown studies that target under-studied human genes. We describe how fraudulent papers may be produced in series by paper mills using what we have described as a ‘theme and variations’ model, which could also be considered a form of salami slicing. We describe features of these single-gene knockdown publications that may allow them to evade detection by journal editors, peer reviewers, and readers. We then propose a number of approaches to facilitate their detection, including improved awareness of the features of publications constructed in series, broader requirements to post submitted manuscripts to preprint servers, and the use of semi-automated literature screening tools. These approaches may collectively improve the detection of fraudulent studies that might otherwise impede future biomarker research.

Since 2000, claims of hearing loss by warfighters have doubled. It is the most frequently identified combat-related disability. Conventional audibility enhancement relies heavily on hearing aids, which do not provide sufficient sound intelligibility for a sizable subset of the hearing-impaired population. For them, there is a surgical option called a ‘cochlear implant’, a device which bypasses the damaged portions of the inner ear (cochlea) and provides direct neural stimulation. In this paper, we review the current state of the art in hearing aids and cochlear implants. A new device which has the potential for high spectral and temporal fidelity, the optical cochlear implant, is currently being tested in the laboratory. The projected development timeline spans many years: from point testing in the laboratory, through the approval process for limited human testing, with control gates for application to human candidates. A model-based development approach could potentially shorten this timeline. In this paper, we describe models and simulations that we developed to extend laboratory measurements in order to evaluate intelligibility impacts. Specifically, we describe our development of the Cochlear Laser Transduction Model, a physics-based simulator that evaluates tonotopic specificity; the Optical Cochlear Implant Simulator (OCIS), which can extend the laboratory measurements via simulation using the results of the Cochlear Laser Transduction Model; and the configuration of an off-the-shelf speech recognition tool to quickly assess intelligibility impacts, predicting system level impacts of varying optical cochlear implant design parameters. Results from the system-level modeling and simulation approach indicate that significant intelligibility improvements could be realized with the optical cochlear implant, with potential to offer upwards of 40 channels of spectral resolution compared with 10 channels with electrode-based implants.

Detailed genomic characterization of cancer specimens is required to identify all genes whose dysregulation contributes to tumorigenesis and/or tumor progression. These include amplification target genes, whose oncogenic functions derive from their overexpression in response to increased gene copy number, and which increasingly serve as therapeutic targets and predictive markers. We propose that identifying novel amplification target genes is becoming more challenging, and may require the comparative analysis of multiple studies mapping gene copy number changes and/or defining associations between gene copy number and expression. We therefore reviewed the array comparative genomic hybridization and single nucleotide polymorphism profiling literature to identify copy number increases that were restricted to chromosome 8q21 in human cancers, which were reported most frequently in breast cancer. We determined the minimal regions of overlap between gained regions and then examined which chromosome 8q21 genes were most frequently overexpressed, or otherwise supported, in individual studies. As these combined approaches supported the previously proposed amplification targets TCEB1, TPD52, and WWP1, the comparison of multiple genomic studies may therefore effectively predict candidate gene amplification targets, and prioritize these for further study.